KBC Group
KYMR icon

KBC Group’s Kymera Therapeutics KYMR Stock Holding History

KBC Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$192K Hold
1,716
– – ﹤0.01% 1034
2026
Q2 		$197K Hold
1,716
– – ﹤0.01% 1054
2026
Q1 		$143K Hold
1,716
– – ﹤0.01% 1116
2025
Q4 		$134K Hold
1,716
– – ﹤0.01% 1109
2025
Q3 		$97K Hold
1,716
– – ﹤0.01% 1279
2025
Q2 		$75K Sell
1,716
-763
-31% -$26.3K ﹤0.01% 1391
2025
Q1 		$68K Buy
2,479
+328
+15% +$12K ﹤0.01% 1692
2024
Q4 		$87K Buy
2,151
+752
+54% +$34K ﹤0.01% 1638
2024
Q3 		$66K Hold
1,399
– – ﹤0.01% 1563
2024
Q2 		$42K Hold
1,399
– – ﹤0.01% 1710
2024
Q1 		$56K Buy
+1,399
New +$50.1K ﹤0.01% 1486

Other funds holding KYMR

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

KBC Group's KYMR Position: Q3 2026 in Review

KBC Group held its Kymera Therapeutics (KYMR) position steady in Q3 2026 at 1,716 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

KBC Group first reported a position in KYMR in Q1 2024 and has held it in 11 quarters since. The position peaked at $197K in Q2 2026. 78 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • KBC Group held 1,716 shares of Kymera Therapeutics worth $192K as of Q3 2026.
  • KBC Group left its Kymera Therapeutics share count unchanged in Q3 2026.
  • Kymera Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1034 holding.
  • KBC Group first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • KBC Group's Kymera Therapeutics position peaked at $197K in Q2 2026.
  • 78 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.